Bioverativ Inc (NASDAQ:BIVV) – Stock analysts at William Blair upped their FY2017 earnings per share (EPS) estimates for Bioverativ in a research note issued to investors on Wednesday. William Blair analyst R. Prasad now anticipates that the biotechnology company will post earnings per share of $2.65 for the year, up from their previous estimate of $2.51. William Blair also issued estimates for Bioverativ’s Q4 2017 earnings at $0.68 EPS and FY2018 earnings at $3.92 EPS.
BIVV has been the subject of a number of other reports. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research report on Monday. Royal Bank of Canada started coverage on Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a research report on Monday, October 23rd. Morgan Stanley restated an “underweight” rating and issued a $47.00 price target (up from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Finally, Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Bioverativ presently has a consensus rating of “Hold” and an average target price of $60.47.
Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis.
A number of institutional investors have recently modified their holdings of BIVV. Advisors Asset Management Inc. purchased a new position in Bioverativ in the third quarter worth approximately $137,000. TCI Wealth Advisors Inc. purchased a new position in Bioverativ in the third quarter worth approximately $186,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in Bioverativ in the third quarter worth approximately $190,000. Canada Pension Plan Investment Board purchased a new position in Bioverativ in the third quarter worth approximately $194,000. Finally, ACG Wealth purchased a new position in Bioverativ in the third quarter worth approximately $205,000. Institutional investors own 95.99% of the company’s stock.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.